Literature DB >> 2649838

Clinicopathologic characteristics of premalignant and malignant melanocytic lesions of the conjunctiva.

F A Jakobiec1, R Folberg, T Iwamoto.   

Abstract

Primary acquired melanosis (PAM), a disease that affects mostly middle-aged white patients, is predominantly a proliferative condition of the melanocytes that normally populate the conjunctival epithelium. Primary acquired melanosis without atypia (low risk for the development of melanoma) is typically created by increased numbers of melanocytes restricted to the basilar region of the epithelium without nuclear hyperchromasia or prominence of the nucleoli. Primary acquired melanosis with atypia, a formal precursor of melanoma, is characterized by the proliferation of small polyhedral cells, spindle cells, large dendritiform melanocytes, or epithelioid cells that may: remain restricted to the basilar region (basilar nests); form nests at all levels of the epithelium; spread individually to all levels of the epithelium (pagetoid extension); or proliferate in a sheet-like fashion approximating a melanoma in situ. Lesions composed of epithelioid cells or exhibiting intraepithelial pagetoid extension have, respectively, a 75 or 90% chance of eventuating in invasive melanoma. Primary acquired melanosis in an adult should not be confused with "a junctional nevus," which is almost always restricted to childhood. Invasive melanomas measuring less than 0.8 mm in thickness tend not to be associated with metastases; the tumor cells may be small polyhedral (in which case confusion with a compound nevus often arises), epithelioid, spindled, or ballooned. Nodules composed of spindle cells in part or in toto tend to have less metastatic potential at a given thickness measurement than comparable nodules composed of epithelioid or polyhedral cells. The clinical features, electron microscopic findings, and biologic principles underwriting clinical management are also presented.

Entities:  

Mesh:

Year:  1989        PMID: 2649838     DOI: 10.1016/s0161-6420(89)32920-4

Source DB:  PubMed          Journal:  Ophthalmology        ISSN: 0161-6420            Impact factor:   12.079


  29 in total

1.  Indeterminate melanocytic proliferations of the conjunctiva.

Authors:  H E Grossniklaus; C E Margo; A R Solomon
Journal:  Trans Am Ophthalmol Soc       Date:  1999

2.  Combined nevi of the conjunctiva.

Authors:  J B Crawford; E L Howes; D H Char
Journal:  Trans Am Ophthalmol Soc       Date:  1999

3.  [Conjunctival malignancies].

Authors:  Claudia Auw-Hädrich; Thomas Reinhard
Journal:  Ophthalmologe       Date:  2019-10       Impact factor: 1.059

4.  Primary acquired melanosis of the conjunctiva: experience with 311 eyes.

Authors:  Jerry A Shields; Carol L Shields; Arman Mashayekhi; Brian P Marr; Raquel Benavides; Archana Thangappan; Laura Phan; Ralph C Eagle
Journal:  Trans Am Ophthalmol Soc       Date:  2007

Review 5.  Updates in Ocular Surface Tumor Diagnostics.

Authors:  Afshan A Nanji; Carolina Mercado; Anat Galor; Sander Dubovy; Carol L Karp
Journal:  Int Ophthalmol Clin       Date:  2017

6.  Management of conjunctival malignant melanoma: a review and update.

Authors:  James R Wong; Afshan A Nanji; Anat Galor; Carol L Karp
Journal:  Expert Rev Ophthalmol       Date:  2014-06

Review 7.  Conjunctival melanoma and melanocytic intra-epithelial neoplasia.

Authors:  N Kenawy; S L Lake; S E Coupland; B E Damato
Journal:  Eye (Lond)       Date:  2012-12-07       Impact factor: 3.775

8.  Topical treatment options for conjunctival neoplasms.

Authors:  Jonathan W Kim; David H Abramson
Journal:  Clin Ophthalmol       Date:  2008-09

9.  Clinical predictive factors for development of recurrence and metastasis in conjunctival melanoma: a review of 68 cases.

Authors:  P De Potter; C L Shields; J A Shields; H Menduke
Journal:  Br J Ophthalmol       Date:  1993-10       Impact factor: 4.638

10.  Cystic benign melanosis of the conjunctiva.

Authors:  Philip W Laird; Maria A Woodward; John G Williams; W Barry Lee; Hans E Grossniklaus
Journal:  Cornea       Date:  2012-11       Impact factor: 2.651

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.